Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma
| Title: | Real-World Evidence: Multicenter Efficacy and Toxicity Analysis of Nintedanib With Docetaxel as Second-Line Treatment in Mexican Patients With Advanced Lung Adenocarcinoma |
|---|---|
| Authors: | Jeronimo Rafael Rodríguez-Cid; Saul Campos-Gomez; Vanessa García-Montes; Manuel Magallanes-Maciel; Rodrigo Rafael Flores-Mariñelarena; Valeria Michelle Fernández-Garibay; Iván Romarico González-Espinoza; Juan Paulo Ceja-García; Juan Carlos Cázarez-Price; Luis Martínez-Barrera; Leopoldo Barriguete-Parra; Carlos Jose Zuloaga-Fernandez; Roberto Kuri-Exsome; David Suárez-García; Jorge Ignacio Gonzalez-Villanueva; Noé Flores-Anaya; Jose Antonio Acevedo-Delgado; Alma Magdalena Astorga-Ramos; Raquel Gerson-Cwilich; Alberto Villalobos-Prieto; Claudia Rodríguez-Silva; Maria Fernanda Noriega-Iriondo; Leticia Vázquez-Cortés; Eusebio Perales-Rodríguez; Alicia Acosta-Espinoza; Yareni Perez-Lozano; Daniel Capdeville-García; Jorge Arturo Alatorre-Alexander |
| Source: | JCO Global Oncology, Vol , Iss 6, Pp 462-470 (2020) |
| Publisher Information: | American Society of Clinical Oncology |
| Publication Year: | 2020 |
| Collection: | Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: | Neoplasms. Tumors. Oncology. Including cancer and carcinogens; RC254-282 |
| Description: | PURPOSEThe LUME-Lung 1 study has brought consistent evidence of the effective use of nintedanib in lung adenocarcinoma as a second line of treatment; however, differences among ethnicities have been found in some studies.METHODSThis was a retrospective review among 21 medical centers of 150 patients with a confirmed diagnosis of lung adenocarcinoma, included in a compassionate use program of nintedanib from March 2014 to September 2015. The current study aimed to analyze the effectiveness of nintedanib in combination with docetaxel in the Mexican population, using progression-free survival rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. In addition, we examined the toxicity profile of our study population as a secondary end point.RESULTSAfter exclusion criteria, only 99 patients met the criteria for enrollment in the current study. From the total study population, 53 patients (53.5%) were male and 46 (46.5%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the compassionate use program. A total of 48 patients (48.5%) had partial response; 26 (26.3%), stable disease; 4 (4%), complete response; and 16 (16.2%), progression; and 5 (5%) were nonevaluable. We found a median progression-free survival of 5 months (95% CI, 4.3 to 5.7 months). The most common grade 3 or 4 adverse reactions were fatigue (14%) and diarrhea (13%).CONCLUSIONNintedanib, as part of a chemotherapy regimen, is an effective option with an acceptable toxicity profile for advanced lung adenocarcinoma after first-line treatment progression. |
| Document Type: | article in journal/newspaper |
| Language: | English |
| Relation: | https://doaj.org/toc/2687-8941; https://doaj.org/article/9d217392ca9447fd9047653acf509678 |
| DOI: | 10.1200/JGO.19.00330 |
| Availability: | https://doi.org/10.1200/JGO.19.00330; https://doaj.org/article/9d217392ca9447fd9047653acf509678 |
| Accession Number: | edsbas.BFCF39C1 |
| Database: | BASE |